Kymab has announced that the Supreme Court of the UK has held that all of the claims of two patents owned by Regeneron Pharmaceuticals that were asserted against Kymab are invalid. The patents in
For now, Formycon cannot launch its biosimilar of the macular degeneration treatment Eylea in various European markets. Munich Regional Court yesterday granted Regeneron and Bayer a preliminary
total 1 pages, 2 items